We showed that reducing platelet counts or using antiplatelet reagents reduced the therapeutic effect of α-PD-L1 antibody in a murine model of ovarian cancer, and increasing platelet counts results in a more robust response. The gene discussed is CD274; the disease is ovarian cancer.